Biogen (BIIB) Acquisitions (2010 - 2024)
Biogen (BIIB) posted quarterly Acquisitions of -$1.1 billion for Q4 2024, down 282.02% year-over-year from $590.5 million in Q1 2024, and down 282.02% on a QoQ basis from $590.5 million in Q4 2023.
Biogen (BIIB) Acquisitions (2010 - 2024) Analysis & Trends
Biogen (BIIB) has reported Acquisitions for 6 consecutive years, with -$1.1 billion the latest figure, recorded in Q4 2024.
- In Q4 2024, Acquisitions fell 282.02% year-over-year to -$1.1 billion; the TTM figure through Dec 2025 stood at -$484.3 million (changed 0.0% YoY), while the FY2023 annual figure was $6.9 billion, changed N/A from the prior year.
- Acquisitions came in at -$1.1 billion for Q4 2024 at Biogen, down from $590.5 million in the prior quarter.
- The five-year high for Acquisitions was $590.5 million in Q4 2023, with the low at -$1.1 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 8.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 109.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.07 Bn |
| Dec 31, 2023 | 590.50 Mn |
| Mar 31, 2015 | 198.80 Mn |
| Mar 31, 2012 | 72.40 Mn |
| Dec 31, 2011 | 5.00 Mn |
| Dec 31, 2010 | 32.50 Mn |
| Mar 31, 2010 | 39.98 Mn |